Wedbush analyst Laura Chico raised the firm’s price target on Travere Therapeutics (TVTX) to $55 from $53 and keeps an Outperform rating on the shares. Despite the Q1 Filspari miss, the firm sees a number of positive forward signals that should keep investors looking ahead to the FSGS launch. First, Patient Start Forms reached a new high and reflected pure IgAN demand. With other agents launching and continued interest, Wedbush sees market expansion and no signs that this may slow in the near term.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- Travere Therapeutics price target raised to $59 from $53 at Citi
- Travere Therapeutics price target raised to $57 from $47 at H.C. Wainwright
- Travere Therapeutics Bets Big on FILSPARI Momentum
- Travere Therapeutics reports Q1 EPS 5c, consensus (5c)
- Travere Therapeutics options imply 5.7% move in share price post-earnings